Myeloperoxidase gene polymorphism predicts fibrosis severity in women with hepatitis C.

Autor: do Carmo RF; Colegiado de Ciências Farmacêuticas, Universidade Federal do Vale do São Francisco, Pernambuco, Brazil; Rede Nordeste de Biotecnologia, Pernambuco, Brazil. Electronic address: rodrigo.carmo@univasf.edu.br., Vasconcelos LR; Instituto do Fígado de Pernambuco, Pernambuco, Brazil., Mendonça TF; Rede Nordeste de Biotecnologia, Pernambuco, Brazil., de Mendonça Cavalcanti Mdo S; Instituto de Ciências Biológicas, Universidade de Pernambuco, Pernambuco, Brazil., Pereira LM; Instituto do Fígado de Pernambuco, Pernambuco, Brazil; Faculdade de Ciências Médias, Universidade de Pernambuco, Pernambuco, Brazil., Moura P; Instituto de Ciências Biológicas, Universidade de Pernambuco, Pernambuco, Brazil.
Jazyk: angličtina
Zdroj: Human immunology [Hum Immunol] 2014 Aug; Vol. 75 (8), pp. 766-70. Date of Electronic Publication: 2014 Jun 02.
DOI: 10.1016/j.humimm.2014.05.008
Abstrakt: Oxidative stress plays an important role on liver fibrosis progression in the course of hepatitis C virus (HCV) infection. Myeloperoxidase (MPO) is an enzyme released by neutrophils and macrophages, responsible for generating hypochlorous acid and reactive oxygen species (ROS) that may lead to liver injury in HCV infection. On the other hand, antioxidant enzymes such as manganese superoxide dismutase (SOD) controls ROS-mediated damage. The aim of the present study was to investigate the influence of MPO G-463A and SOD2 Ala16Val polymorphisms in the severity of liver fibrosis in individuals with chronic HCV infection. The present study included 270 patients with chronic HCV recruited from the Gastrohepatology Service of the Oswaldo Cruz University Hospital/Liver Institute of Pernambuco (Recife, Northeastern Brazil). All patients underwent liver biopsy, which was classified according METAVIR score. The SNPs were determined by real-time PCR. After multivariate analysis adjustment, the GG genotype of MPO and the presence of metabolic syndrome were independently associated with fibrosis severity in women (P = 0.025 OR 2.25 CI 1.10-4.59 and P = 0.032 OR 2.32 CI 1.07-5.01, respectively). The presence of the GG genotype seems to be a risk factor for fibrosis severity in women with HCV.
(Copyright © 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: